Oncology
Cancer clinical trials
Studies of cancers and tumors of every type and site, from prevention to treatment. We’re tracking 20,663 recruiting studies in this area right now.
By phase
- Not applicable9,825
- Phase 24,462
- Phase 12,741
- Phase 1/Phase 21,689
- Phase 31,402
- Phase 2/Phase 3281
- Phase 4263
Top conditions
- Breast Cancer1,228
- Cancer660
- Prostate Cancer657
- Colorectal Cancer496
- Lung Cancer428
- Ovarian Cancer337
- Multiple Myeloma329
- Gastric Cancer300
- Pancreatic Cancer295
- Acute Myeloid Leukemia293
- Hepatocellular Carcinoma284
- Solid Tumor258
- Advanced Solid Tumor256
- Cervical Cancer231
- Head and Neck Cancer229
- Endometrial Cancer204
- Advanced Solid Tumors195
- Esophageal Cancer193
Leading sponsors
- M.D. Anderson Cancer Center451
- Fudan University313
- Sun Yat-sen University290
- Memorial Sloan Kettering Cancer Center289
- National Cancer Institute (NCI)288
- Mayo Clinic238
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences151
- City of Hope Medical Center144
- AstraZeneca133
- University Health Network, Toronto125
Where studies are running
- California1,428
- Texas640
- Arizona513
- Florida446
- Alabama420
- New York411
- Massachusetts339
- Maryland329
- New Jersey268
- Pennsylvania242
Recruiting studies20,663 total
- NCT05067101Recruiting
Compare two bladder cancer surgeries in men
This trial compares two types of bladder surgery to see which works better for certain men with bladder cancer. It may help you and your doctors choose the safest option that controls the cancer while preserving quality of life.
Guangzhou, GuangdongAges 20 years+ - NCT05067348RecruitingPhase 2
Tocilizumab for generalized myasthenia gravis symptoms
This trial tests whether tocilizumab can improve symptoms and safety in people with generalized myasthenia gravis (MG) who already take standard MG treatments. It may help if your weakness is still significant despite current therapy.
Beijing, Beijing MunicipalityAges 18–80 - NCT05067764Recruiting
Aponeurectomy for reducing Dupuytren’s disease return rate
This study looks at whether a specific hand/cord procedure called aponeurectomy can lower how often Dupuytren’s disease comes back within 2 years. You might be offered surgery and then followed to see how well your symptoms and tightness improve and how often they return.
PessacAges 18 years+ - NCT05068232RecruitingPhase 2
Durvalumab plus targeted radiation for metastatic small cell lung cancer
This Phase 2 study tests durvalumab (an immunotherapy) together with focused, ablative radiation to treat metastatic small cell lung cancer. It may help shrink tumors and improve outcomes, especially when at least one tumor can be safely targeted with this radiation plan.
Chicago, IllinoisAges 18 years+ - NCT05068310Recruiting
Test a high-detail eye-like scan on skin tumors before biopsy
This study tests a high-resolution scan (called OCT) to better see skin tumors before they’re removed or biopsied. It may help doctors evaluate both non-pigmented and pigmented skin spots that look like possible skin cancer.
BerlinAges 18 years+ - NCT05068531Recruiting
Detecting early treatment failure in stage IV colon cancer
This study looks for early signs that treatment is not working in people with stage IV colon or rectal cancer that has spread only to the liver. It may help doctors adjust care sooner by using regular blood, stool, and tissue samples around liver procedures.
Montreal, QuebecAges 18 years+ - NCT05069220RecruitingEarly Phase 1
PET/CT scan to study neural crest tumors
This early-phase trial uses a special PET/CT scan to help evaluate neural crest tumors, which include conditions like neuroblastoma. It may help doctors understand how well the scan shows tumor activity to guide diagnosis and treatment planning.
Beijing, DongchengAges 1–80 - NCT05071937RecruitingPhase 2
Talazoparib plus ZEN003694 for recurrent ovarian cancer
This Phase 2 trial tests whether combining ZEN003694 with talazoparib can slow or shrink recurrent ovarian, fallopian tube, or primary peritoneal cancer. It is designed for people who have already been treated with a PARP inhibitor before, and it may help if that cancer comes back.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT05069857RecruitingPhase 2
New pre-surgery treatment tailored to cancer markers in mouth cancer
This Phase 2 study tests medicines given before surgery for stage III/IV oral squamous cell carcinoma, choosing the treatment based on your tumor marker results. It aims to shrink the cancer and improve outcomes by using two targeted types of therapy.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05072600RecruitingPhase 2
Pembrolizumab after complete bladder cancer treatment response
This trial studies pembrolizumab (an immunotherapy) in people with muscle-invasive bladder cancer who had a combined “trimodality” treatment and then achieved a complete response. The goal is to help control the cancer after the initial treatment is finished.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05072041Recruiting
Degradable chemo bead treatment for liver cancer
This trial studies a new type of “degradable” chemo bead delivered through a catheter to treat hepatocellular carcinoma (HCC). It aims to check safety and whether the treatment works when surgery or transplant is not an option.
Seoul, SeoulAges 19–79 - NCT05074290RecruitingPhase 1/Phase 2
Testing safety and drug levels of a breast cancer drug plus taxane
This early-phase study tests how epidiferphane works in the body and whether it is safe when combined with standard chemotherapy “taxanes” (paclitaxel or docetaxel) for breast cancer. If you qualify, you may be starting a new taxane treatment plan at the study site, and you would be followed closely for side effects and drug levels.
Gainesville, FloridaAges 18–99 - NCT05076682RecruitingPhase 2
Study for hard-to-treat triple-negative breast cancer that keeps growing
This Phase 2 trial tests a treatment plan for triple-negative breast cancer that has come back or kept progressing after prior immunotherapy (sometimes along with targeted therapy or chemotherapy). It may help by trying to make the cancer more controllable when it has become resistant to earlier treatment.
ShanghaiAges 18–70 - NCT05076500Recruiting
How radiotherapy changes a tumor’s immune response
This study looks at how a tumor’s immune system responds when you receive radiotherapy. It involves taking a planned pre-treatment biopsy so researchers can study immune and tumor changes and see if radiotherapy affects them.
ManchesterAges 18 years+ - NCT05076760RecruitingPhase 1
Study of a cancer-killing virus with standard treatments
This Phase 1 trial tests MEM-288, an oncolytic (cancer-killing) virus, either alone or combined with standard cancer medicines, in people with advanced solid tumors. It’s designed to see how the treatment works and how safe it is in different cancer types and after specific prior therapies.
Tampa, FloridaAges 18 years+ - NCT05076942RecruitingPhase 2
Study of sentinel lymph nodes in vulvar cancer
This Phase 2 study looks at how vulvar squamous cell cancer (SCC) spreads to the sentinel lymph node, and how findings may guide treatment. It focuses on specific early-stage tumor features and requires that cancer is found in the sentinel lymph node.
Orange, CaliforniaAges 18 years+ - NCT05078528Recruiting
Low-cost imaging test during cervical follow-up
This study tests a low-cost imaging approach during colposcopy, for people who have abnormal cervical screening results or need follow-up after prior abnormal cells. It may help clinics detect cervical changes more easily and at lower cost.
Porto Alegre, Rio Grande do SulAges 25 years+ - NCT05078671RecruitingPhase 4
Testing a drug-boost to improve olaparib levels and side effects
This Phase 4 study tests whether adding a “booster” medicine can raise olaparib levels in the body so it may be better tolerated and more cost-effective. You may be eligible if you are already taking olaparib and meet health and medication safety requirements.
's-HertogenboschAges 18 years+ - NCT05079282RecruitingPhase 1
Study drug for relapsed or treatment-resistant T-cell lymphoma
This early-phase (Phase 1) study tests ONO-4685 in adults whose T-cell lymphoma has come back or did not respond to treatment. It aims to find a safe dose and see whether it can shrink lymphoma in people with limited options.
Birmingham, AlabamaAges 18 years+ - NCT05079763Recruiting
Hydrogel treatment to reduce skin damage after breast radiation
This trial tests a bacterial cellulose–based gel with a soothing ingredient (monolaurin) to help prevent or lessen painful skin reactions in the area receiving breast radiation. It focuses on people who have already finished surgery and chemotherapy and are about to start a planned radiation treatment schedule.
ManilaAges 18–80 - NCT05080556RecruitingPhase 2
Adaptive chemotherapy for ovarian cancer after platinum and PARP
This trial tests a personalized (adaptive) chemotherapy plan for people with certain types of ovarian/fallopian tube/peritoneal cancer who already had platinum chemotherapy and a PARP inhibitor. It’s for patients whose cancer came back after (or still responds to) prior platinum treatment and may help delay disease progression.
LondonAges 18 years+ - NCT05080010RecruitingPhase 3
Extra chemo after eye removal for high-risk retinoblastoma
This Phase 3 study tests whether giving chemotherapy after the eye has been removed can lower the chance of retinoblastoma coming back for children with high-risk disease. You may be screened if your child had one eye affected and meet the staging and treatment history requirements.
Guangzhou, GuangdongAges Any age - NCT05081024Recruiting
Blood test biomarker to help preserve organs in rectal cancer
This study looks at a blood test (ctDNA, a way to detect cancer DNA in the bloodstream) to help doctors choose treatment that may spare organs for people with stage II–III rectal cancer. You may be followed to see how well the blood test can guide treatment decisions.
Portland, OregonAges 18 years+ - NCT05083247RecruitingPhase 2
Pre-surgery chemotherapy plus targeted radiation for borderline pancreatic cancer
This trial studies whether giving chemotherapy before surgery, and possibly adding a focused high-dose radiation treatment, can improve outcomes for people with borderline resectable pancreatic cancer. It aims to shrink or control the cancer and help more patients get to surgery safely.
AntwerpAges 18 years+
Common questions
- How many cancer clinical trials are recruiting?
- Clin2 is tracking 20,663 recruiting oncology studies from the U.S. registry right now, out of 31,727 we cover in this area in total.
- What does “Cancer” cover here?
- Studies of cancers and tumors of every type and site, from prevention to treatment. We group each study into cancer based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a cancer trial near me?
- Use the search to filter cancer studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.